Skip to main navigation Skip to search Skip to main content

A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy

  • So Hyun Bae
  • , Jang Won Heo
  • , Cinoo Kim
  • , Tae Wan Kim
  • , Joo Yong Lee
  • , Su Jeong Song
  • , Tae Kwann Park
  • , Sang Woong Moon
  • , Hum Chung
  • Seoul National University
  • Incheon Medical Center
  • University of Ulsan
  • Soonchunhyang University
  • Kyung Hee University

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To report 6-month outcomes of a prospective, randomized study comparing the efficacy and safety between low-fluence photodynamic therapy (PDT) and intravitreal injections of ranibizumab in the treatment of chronic central serous chorioretinopathy. Design: Prospective, randomized, single-center pilot study. Methods: Sixteen eyes with chronic central serous chorioretinopathy were randomized to receive either low-fluence PDT or intravitreal injections of ranibizumab: 8 eyes in the low-fluence PDT group and 8 in the ranibizumab group. Rescue treatment was considered if subretinal fluid was sustained after completion of primary treatment: low-fluence PDT for the ranibizumab group and ranibizumab injection for the low-fluence PDT group. Main outcome measures were excess foveal thickness, resolution of subretinal fluid, choroidal perfusion on indocyanine green angiography, and best-corrected visual acuity. Results: At 3 months, the mean excess foveal thickness was reduced from 74.1 ± 56.0 μm to -35.4 ± 44.5 μm in the low-fluence PDT group (P =.017) and from 26.3 ± 50.6 μm to -23.1 ± 56.5 μm in the ranibizumab group (P =.058). After a single session of PDT, 6 eyes (75%) in the low-fluence PDT group achieved complete resolution of subretinal fluid and reduction of choroidal hyperpermeability, whereas 2 (25%) eyes in the ranibizumab group achieved this after consecutive ranibizumab injections. Four eyes (50%) in the ranibizumab group underwent additional low-fluence PDT and accomplished complete resolution. At 3 months, significant improvement of best-corrected visual acuity was not demonstrated in the low-fluence PDT group (P =.075), whereas it was observed in the ranibizumab group (P =.012). However, the tendency toward improvement of best-corrected visual acuity was not maintained. Conclusions: In terms of anatomic outcomes, the effect of ranibizumab injections was not promising compared with that of low-fluence PDT.

Original languageEnglish
Pages (from-to)784-792.e2
JournalAmerican Journal of Ophthalmology
Volume152
Issue number5
DOIs
StatePublished - Nov 2011

Fingerprint

Dive into the research topics of 'A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy'. Together they form a unique fingerprint.

Cite this